Lars Dreesmann Named President of Boehringer Ingelheim Fremont, Inc.
FREMONT, Calif., Oct. 1, 2020 /PRNewswire/ -- Boehringer Ingelheim today announced that Lars Dreesmann, PhD, has been named President of the company's US biopharmaceutical development and manufacturing business, Boehringer Ingelheim Fremont, Inc., effective October 1st, 2020. Most recently, Dr. Dreesmann was Head of Global Quality Systems & Product Compliance Biopharma for Boehringer Ingelheim, a role he has held since January 2019. In his new role, Dr. Dreesmann will report to Jean-Michel Boers, U.S. Country Managing Director, President & CEO, Boehringer Ingelheim.
"We are extremely pleased to have Lars take on the leadership of our US biopharmaceuticals business during this critical time of growth," said Jean-Michel Boers, US Country Managing Director, President & CEO, Boehringer Ingelheim. "He is a proven leader with a keen scientific mind and a deep understanding of our business, which he gained during his more than a dozen years in Boehringer Ingelheim's global Biopharmaceuticals headquarters. We wish Lars much success in his new role."
Dr. Dreesmann joined Boehringer Ingelheim in 2007, after earning his PhD in Neurobiology at the University of Tuebingen & University of Hohenheim in Germany. Since joining the company, Dr. Dreesmann has held a series of leadership roles with increasing levels of responsibility within the company's Biopharmaceuticals headquarters in Germany. His research has been published in multiple scientific and medical journals and he holds a patent in the field of neurobiology.
"I'm thrilled to take on this opportunity and humbled by the trust placed in me by senior leadership," said Lars Dreesmann, PhD, President of Boehringer Ingelheim Fremont, Inc. "In my past roles, I've had the opportunity to work with some of the smart, talented members of the US Biopharmaceuticals team. Now I look forward to the chance to more closely collaborate with and learn from this great group as we continue to distinguish ourselves as the leading biopharmaceutical manufacturing organization. On a personal note, my family and I are excited to make our new home in the San Francisco Bay Area."
About Boehringer Ingelheim Fremont, Inc.
About Boehringer Ingelheim
As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of around $21.3 billion (€19 billion). Our significant investment of over $3.9 billion (€3.5 billion) in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.
We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.
Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation and is part of the Boehringer Ingelheim group of companies. In addition, there are Boehringer Ingelheim Animal Health in Duluth, GA and Boehringer Ingelheim Fremont, Inc. in Fremont, CA.
Boehringer Ingelheim is committed to improving lives and strengthening our communities. Please visit www.boehringer-ingelheim.us/csr to learn more about Corporate Social Responsibility initiatives.
For more information, please visit www.boehringer-ingelheim.us, or follow us on Twitter @BoehringerUS.
View original content to download multimedia:http://www.prnewswire.com/news-releases/lars-dreesmann-named-president-of-boehringer-ingelheim-fremont-inc-301142412.html
SOURCE Boehringer Ingelheim Pharmaceuticals